title: Stimulation of lymphocyte anti-melanoma activity by co-cultured macrophages activated by complex homeopathic medication.
abstract: BACKGROUND
  Melanoma is the most aggressive form of skin cancer, and the most rapidly expanding cancer in terms of worldwide incidence. Chemotherapeutic approaches to treat melanoma have been uniformly disappointing. A Brazilian complex homeopathic medication (CHM), used as an immune modulator, has been recommended for patients with depressed immune systems. Previous studies in mice have demonstrated that the CHM activates macrophages, induces an increase in the number of leukocytes and improves the murine response against Sarcoma-180.
  
  
  METHODS
  Here we studied the interaction of mouse lymph node lymphocytes, co-cultured in vitro with macrophages in the presence or absence of the CHM, with B16F10 melanoma cells.
  
  
  RESULTS
  Lymphocytes co-cultured with macrophages in the presence of the CHM had greater anti-melanoma activity, reducing melanoma cell density and increasing the number of lysed tumor cells. There was also a higher proportion of activated (CD25+) lymphocytes with increased viability. Overall, lymphocytes activated by treatment destroyed growing cancer cells more effectively than control lymphocytes.
  
  
  CONCLUSIONS
  Co-culture of macrophages with lymphocytes in the presence of the CHM enhanced the anti-cancer performance of lymphocytes against a very aggressive lineage of melanoma cells. These results suggest that non-toxic therapies using CHMs are a promising alternative approach to the treatment of melanomas. In addition, they are attractive combination-therapy candidates, which may enhance the efficacy of conventional medicines by improving the immune response against tumor cells.
authors.affiliation: Departamento de Biologia Celular, Laboratório de Pesquisa em Células Inflamatórias e Neoplásicas, Universidade Federal do Paraná (UFPR), Curitiba - PR, Brazil. ferbiocel@yahoo.com.br
authors.forename: Fernando S F
authors.initials: FS
authors.lastname: Guimarães
authors.forename: Ana P R
authors.initials: AP
authors.lastname: Abud
authors.forename: Simone M
authors.initials: SM
authors.lastname: Oliveira
authors.forename: Carolina C
authors.initials: CC
authors.lastname: Oliveira
authors.forename: Beatriz
authors.initials: B
authors.lastname: César
authors.forename: Lucas F
authors.initials: LF
authors.lastname: Andrade
authors.forename: Lucélia
authors.initials: L
authors.lastname: Donatti
authors.forename: Juarez
authors.initials: J
authors.lastname: Gabardo
authors.forename: Edvaldo S
authors.initials: ES
authors.lastname: Trindade
authors.forename: Dorly F
authors.initials: DF
authors.lastname: Buchi
mesh_terms: D000818:Animals; D045744:Cell Line, Tumor; D002478:Cells, Cultured; D018920:Coculture Techniques; D003602:Cytotoxicity, Immunologic; D008214:Lymphocytes / Q000187:drug effects* / Q000276:immunology; D008262:Macrophage Activation / Q000187:drug effects; D008264:Macrophages / Q000187:drug effects* / Q000276:immunology; D008297:Male; D008419:Materia Medica / Q000494:pharmacology*; D008545:Melanoma / Q000188:drug therapy / Q000276:immunology*; D051379:Mice
chemical_list: D008419:Materia Medica
references.citation: Homeopathy. 2005 Jan;94(1):26-32
references.pmid: 15751331
references.citation: Clin Cancer Res. 2006 May 15;12(10):3130-6
references.pmid: 16707612
references.citation: Eur J Cancer. 2006 Apr;42(6):745-50
references.pmid: 16517151
references.citation: Oncol Res. 2006;16(5):211-6
references.pmid: 17294801
references.citation: Annu Rev Immunol. 2006;24:175-208
references.pmid: 16551247
references.citation: Cancer Cell. 2002 Sep;2(3):169-71
references.pmid: 12242147
references.citation: Cytokine Growth Factor Rev. 2003 Oct;14(5):361-8
references.pmid: 12948519
references.citation: CA Cancer J Clin. 2000 Jul-Aug;50(4):215-36; quiz 237-40
references.pmid: 10986965
references.citation: J Submicrosc Cytol Pathol. 2002 Jul;34(3):255-63
references.pmid: 12408358
references.citation: J Cell Biochem. 2008 Jul 1;104(4):1364-77
references.pmid: 18286468
references.citation: Cell. 2002 Jun 14;109(6):707-18
references.pmid: 12086670
references.citation: Micron. 2008 Jun;39(4):461-70
references.pmid: 17379529
references.citation: Eur J Cancer. 2001 Sep;37(13):1709-18
references.pmid: 11527700
references.citation: Science. 2002 Oct 25;298(5594):850-4
references.pmid: 12242449
references.citation: Mol Cell Biochem. 2003 Nov;253(1-2):339-45
references.pmid: 14619985
references.citation: Nat Immunol. 2001 Jun;2(6):487-92
references.pmid: 11376334
references.citation: Cytokine Growth Factor Rev. 2002 Apr;13(2):169-83
references.pmid: 11900992
references.citation: Nat Rev Immunol. 2003 Jan;3(1):23-35
references.pmid: 12511873
references.citation: Immunol Lett. 2006 Aug 15;106(2):135-43
references.pmid: 16769127
references.citation: Eur J Cancer. 2006 Feb;42(3):282-9
references.pmid: 16376071
references.citation: Genet Mol Res. 2003 Jun 30;2(2):223-8
references.pmid: 14966688
references.citation: Nat Immunol. 2001 Jul;2(7):585-9
references.pmid: 11429541
references.citation: Cell Struct Funct. 1993 Dec;18(6):399-407
references.pmid: 8033221
references.citation: Lancet. 2005 Feb 19-25;365(9460):687-701
references.pmid: 15721476
references.citation: Micron. 2006;37(3):277-87
references.pmid: 16364649
references.citation: J Am Coll Surg. 2005 Sep;201(3):418-25
references.pmid: 16125076
references.citation: Cell Biol Int. 2006 Oct;30(10):808-16
references.pmid: 16884931
references.citation: J Infect. 2006 Jun;52(6):420-32
references.pmid: 16386798
references.citation: J Infect. 2005 Aug;51(2):157-64
references.pmid: 16038768